Age
Item
1. Patients aged >=18 years
boolean
C0001779 (UMLS CUI [1])
disease CD20 positive
Item
Trial Protocol Version 1.0: 2. CD20 positive disease
boolean
C0012634 (UMLS CUI [1,1])
C3888518 (UMLS CUI [1,2])
Diagnosis lymphoma
Item
3. Histologically proven diagnosis of diffuse large cell B-cell lymphoma, follicular lymphoma IIIB or transformed indolent lymphoma according to the World Health Organization classification (central pathology review)
boolean
C0011900 (UMLS CUI [1,1])
C0024299 (UMLS CUI [1,2])
Relapsed disease
Item
4. Relapsed disease
boolean
C0277556 (UMLS CUI [1])
ECOG performance status
Item
5. ECOG performance status =< 2, unless tumor associated
boolean
C1520224 (UMLS CUI [1])
LVEF
Item
Trial protocol version 1.0: 6. LVEF >= 45% and normal serum troponin
boolean
C0428772 (UMLS CUI [1])
cardiac reserve
Item
Trial protocol Version 2.0: 6. Adequate cardiac reserve
boolean
C0232164 (UMLS CUI [1,1])
C2347957 (UMLS CUI [1,2])
cure no
Item
7. No curative option available
boolean
C1880198 (UMLS CUI [1,1])
C1298908 (UMLS CUI [1,2])
tumor mass
Item
8. At least 1 measurable tumor mass (>1.5 cm x >1.0 cm) or bone marrow infiltration
boolean
C3273930 (UMLS CUI [1])
informed consent signed
Item
9. Signed informed consent
boolean
C0742766 (UMLS CUI [1])
bone marrow hepatic and renal function
Item
10. Adequate bone marrow reserve / hepatic and renal function
boolean
C0005953 (UMLS CUI [1,1])
C2347957 (UMLS CUI [1,2])
C0232741 (UMLS CUI [1,3])
C0232804 (UMLS CUI [1,4])
Hepatitis B Hepatitis C HIV-infection
Item
11. No active Hepatitis B or C or HIV-infection
boolean
C0019163 (UMLS CUI [1,1])
C0019196 (UMLS CUI [1,2])
C0019693 (UMLS CUI [1,3])
creatinine clearance
Item
12. Measured or calculated creatinine clearance > 30 ml/min
boolean
C0812399 (UMLS CUI [1])
Fresh tumor biopsy
Item
13. Fresh tumor biopsy or archived tissue available
boolean
C0475358 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C2827486 (UMLS CUI [1,3])
compliance
Item
14. Ability of patient to understand nature, importance and individual consequences of clinical trial
boolean
C1321605 (UMLS CUI [1])
childbearing potential post-menopausal
Item
15. Women post-menopausal for more than two years can participate in the trial. Women with childbearing potential can only participate, if they are surgically sterile or a negative pregnancy test (Serum or Urine) is available before trial and they are willing to practice a highly effective and medically accepted contraception method during trial and for a period of 18 months post-treatment.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0232970 (UMLS CUI [1,3])
contraception male patients
Item
16. Male patients are advised to use contraceptive methods (preferably barrier) during treatment and for a period of 6 months post-treatment
boolean
C0086580 (UMLS CUI [1])